Please login to the form below
90TEN appoints new associate director
Stephanie O’Hagan joins the firm from Ketchum
Global healthcare communications consultancy 90TEN has appointed Stephanie O’Hagan as an associate director for the agency’s PR division.
She joins 90TEN from Ketchum, where she served as a senior account director, and she has overseen a number of global pharmaceutical client accounts.
Prior to her role at Ketchum, O’Hagan has served at the likes of Havas Lynx and Oglivy Healthworld in communications and digital roles.
Peter Impey, director of PR at 90TEN, said: “Stephanie’s appointment strategically expands our expertise in delivering creative communications campaigns that deliver life-changing results for patients and clients.”
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
